vaccine candidate, reported news agency Reuters. France's Sanofi and Britain's GSK in May kicked off global trials to include more than 35,000 adults to test the dose.
They hope to get approvals by the end of 2021 after early-stage results showed the vaccine produces a robust immune response, the report added.
The Indian arm of the studies will enroll nearly 3,000 adults between the ages of 18 years and 55 years, as per India's clinical trial registry.
The assessment is expected to run for a year and the first enrolment in India is shown to have been made on Tuesday. "As the virus continues to evolve, we are anticipating what will be needed in the coming months and years, and accordingly, have adapted our vaccine development program,"